Fever After Vaccination Against SARS-CoV-2 with MRNA-Based Vaccine Associated with Higher Antibody Levels During 6 Months Follow-Up

Overview

Journal Vaccines (Basel)

Date 2022 Mar 26

PMID 35335080

Authors

Andrea Kanizsai

Tihamer Molnar

Reka Varnai

Laszlo Zavori

Margit Tokes-Fuzesi

Zoltan Szalai

Janos Berecz

Peter Csecsei

Affiliations

Soon will be listed here.

Abstract

Background: The effect of post-vaccination adverse events on immunogenicity is unknown. We aimed to explore relationship between post-vaccination adverse reactions and antibody levels during 6-month follow-up.

Methods: Blood was serially drawn from healthcare workers after the second dose of BNT162b2 mRNA vaccine (Day 12, 30, 60, 90, 120, 150, and 180) and anti-SARS-CoV-2 spike IgG (S-IgG) levels were measured. Following each vaccine dose, volunteers completed a questionnaire regarding adverse reactions (symptomatic vs. asymptomatic groups).

Results: A total of 395 subjects received the second dose of the vaccine. The main results were as follows: (i) fever after the 2nd dose was independently associated with the median S-IgG level at all follow-up time points; (ii) significantly higher S-IgG levels were observed in the symptomatic group of patients without prior COVID-19 infection throughout the entire follow-up period; (iii) prior COVID-19 positivity resulted in higher S-IgG levels only in the asymptomatic group from Day 90 of the follow-up period; (iv) both prior COVID-19 disease with asymptomatic status and symptomatic status without prior COVID-19 infection resulted in similar S-IgG antibody levels; (v) significantly lower serum S-IgG levels were observed in smokers.

Conclusion: Fever may play an important role in the post-vaccination immune response in the long term.

Citing Articles

Longitudinal study on immunologic, lipoproteomic, and inflammatory responses indicates the safety of sequential COVID-19 vaccination.

Lang J, Bernal A, Wist J, Egan S, Bong S, Millet O J Mol Med (Berl). 2025; .

PMID: 40074874 DOI: 10.1007/s00109-025-02527-y.

Modeling and predicting individual variation in COVID-19 vaccine-elicited antibody response in the general population.

Nakamura N, Kobashi Y, Kim K, Park H, Tani Y, Shimazu Y PLOS Digit Health. 2024; 3(5):e0000497.

PMID: 38701055 PMC: 11068210. DOI: 10.1371/journal.pdig.0000497.

Genotoxicity and safety pharmacology of the rVSVInd(GML)-mspSGtc vaccine against SARS-CoV-2 in Sprague-Dawley rats and Beagle dogs.

Park S, Park H, Back S, Lee Y, Seo J, Kim D Arch Toxicol. 2024; 98(7):2185-2197.

PMID: 38607375 DOI: 10.1007/s00204-024-03746-x.

Anti-tumor necrosis factor therapy is associated with attenuated humoral response to SARS-COV-2 vaccines in patients with inflammatory bowel disease.

Ferreira F, Rafael M, Coimbra L, Boavida N, Arrobas F, Correia F Vaccine. 2023; 41(26):3862-3871.

PMID: 37202269 PMC: 10165058. DOI: 10.1016/j.vaccine.2023.05.012.

Risk of Repeated Adverse Effects following Booster Dose of mRNA COVID-19 Vaccine: Results from the MOSAICO Study.

Ferrara P, Ponticelli D, Losa L, Romeo C, Magliuolo R, Vitale A Vaccines (Basel). 2023; 11(2).

PMID: 36851125 PMC: 9959434. DOI: 10.3390/vaccines11020247.

References

Hanson D . Fever, temperature, and the immune response. Ann N Y Acad Sci. 1997; 813:453-64. DOI: 10.1111/j.1749-6632.1997.tb51733.x. View

Tarbiah N, Todd I, Tighe P, Fairclough L . Cigarette smoking differentially affects immunoglobulin class levels in serum and saliva: An investigation and review. Basic Clin Pharmacol Toxicol. 2019; 125(5):474-483. DOI: 10.1111/bcpt.13278. View

Haas J, Bender F, Ballou S, Kelley J, Wilhelm M, Miller F . Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022; 5(1):e2143955. PMC: 8767431. DOI: 10.1001/jamanetworkopen.2021.43955. View

Saleh E, Moody M, Walter E . Effect of antipyretic analgesics on immune responses to vaccination. Hum Vaccin Immunother. 2016; 12(9):2391-402. PMC: 5027726. DOI: 10.1080/21645515.2016.1183077. View

Muller L, Andree M, Moskorz W, Drexler I, Walotka L, Grothmann R . Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination. Clin Infect Dis. 2021; 73(11):2065-2072. PMC: 8135422. DOI: 10.1093/cid/ciab381. View

Coggins S, Laing E, Olsen C, Goguet E, Moser M, Jackson-Thompson B . Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers. Open Forum Infect Dis. 2022; 9(1):ofab575. PMC: 8759445. DOI: 10.1093/ofid/ofab575. View

Ebinger J, Fert-Bober J, Printsev I, Wu M, Sun N, Prostko J . Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021; 27(6):981-984. PMC: 8205849. DOI: 10.1038/s41591-021-01325-6. View

Hwang Y, Song K, Choi Y, Go S, Choi S, Jung J . Can reactogenicity predict immunogenicity after COVID-19 vaccination?. Korean J Intern Med. 2021; 36(6):1486-1491. PMC: 8588964. DOI: 10.3904/kjim.2021.210. View

Ryan E, Pollock S, Pollack S, Murant T, Bernstein S, Felgar R . Activated human B lymphocytes express cyclooxygenase-2 and cyclooxygenase inhibitors attenuate antibody production. J Immunol. 2005; 174(5):2619-26. DOI: 10.4049/jimmunol.174.5.2619. View

10.

Yoda T, Katsuyama H . Willingness to Receive COVID-19 Vaccination in Japan. Vaccines (Basel). 2021; 9(1). PMC: 7828811. DOI: 10.3390/vaccines9010048. View

11.

Naaber P, Tserel L, Kangro K, Sepp E, Jurjenson V, Adamson A . Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021; 10:100208. PMC: 8418937. DOI: 10.1016/j.lanepe.2021.100208. View

12.

Andrews N, Walker W, Finn A, Heath P, Collinson A, Pollard A . Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. Vaccine. 2011; 29(45):7913-9. DOI: 10.1016/j.vaccine.2011.08.076. View

13.

Fischinger S, Boudreau C, Butler A, Streeck H, Alter G . Sex differences in vaccine-induced humoral immunity. Semin Immunopathol. 2018; 41(2):239-249. PMC: 6373179. DOI: 10.1007/s00281-018-0726-5. View

14.

Skok M, Grailhe R, Agenes F, Changeux J . The role of nicotinic receptors in B-lymphocyte development and activation. Life Sci. 2007; 80(24-25):2334-6. DOI: 10.1016/j.lfs.2007.02.005. View

15.

Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615. PMC: 7745181. DOI: 10.1056/NEJMoa2034577. View

16.

Morales-Nunez J, Munoz-Valle J, Meza-Lopez C, Wang L, Machado Sulbaran A, Torres-Hernandez P . Neutralizing Antibodies Titers and Side Effects in Response to BNT162b2 Vaccine in Healthcare Workers with and without Prior SARS-CoV-2 Infection. Vaccines (Basel). 2021; 9(7). PMC: 8310237. DOI: 10.3390/vaccines9070742. View

17.

Qiu F, Liang C, Liu H, Zeng Y, Hou S, Huang S . Impacts of cigarette smoking on immune responsiveness: Up and down or upside down?. Oncotarget. 2016; 8(1):268-284. PMC: 5352117. DOI: 10.18632/oncotarget.13613. View

18.

Held J, Esse J, Tascilar K, Steininger P, Schober K, Irrgang P . Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty). Vaccines (Basel). 2021; 9(10). PMC: 8539109. DOI: 10.3390/vaccines9101063. View

19.

Bancos S, Bernard M, Topham D, Phipps R . Ibuprofen and other widely used non-steroidal anti-inflammatory drugs inhibit antibody production in human cells. Cell Immunol. 2009; 258(1):18-28. PMC: 2693360. DOI: 10.1016/j.cellimm.2009.03.007. View

20.

Ali H, Alahmad B, Al-Shammari A, Alterki A, Hammad M, Cherian P . Previous COVID-19 Infection and Antibody Levels After Vaccination. Front Public Health. 2021; 9:778243. PMC: 8671167. DOI: 10.3389/fpubh.2021.778243. View